195 related articles for article (PubMed ID: 24173007)
1. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.
Martin ST; Powell JT; Patel M; Tsapepas D
Am J Health Syst Pharm; 2013 Nov; 70(22):1977-83. PubMed ID: 24173007
[TBL] [Abstract][Full Text] [Related]
2. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
3. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
Larsen CP; Grinyó J; Medina-Pestana J; Vanrenterghem Y; Vincenti F; Breshahan B; Campistol JM; Florman S; Rial Mdel C; Kamar N; Block A; Di Russo G; Lin CS; Garg P; Charpentier B
Transplantation; 2010 Dec; 90(12):1528-35. PubMed ID: 21076381
[TBL] [Abstract][Full Text] [Related]
4. Belatacept in kidney transplantation.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2012 Dec; 17(6):640-7. PubMed ID: 23044530
[TBL] [Abstract][Full Text] [Related]
5. Biological agents in kidney transplantation: belatacept is entering the field.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
[TBL] [Abstract][Full Text] [Related]
6. Risk evaluation and mitigation strategies: a focus on belatacept.
Sam T; Gabardi S; Tichy EM
Prog Transplant; 2013 Mar; 23(1):64-70. PubMed ID: 23448823
[TBL] [Abstract][Full Text] [Related]
7. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.
Rostaing L; Neumayer HH; Reyes-Acevedo R; Bresnahan B; Florman S; Vitko S; Heifets M; Xing J; Thomas D; Vincenti F
Clin J Am Soc Nephrol; 2011 Nov; 6(11):2696-704. PubMed ID: 21921152
[TBL] [Abstract][Full Text] [Related]
8. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.
Pestana JO; Grinyo JM; Vanrenterghem Y; Becker T; Campistol JM; Florman S; Garcia VD; Kamar N; Lang P; Manfro RC; Massari P; Rial MD; Schnitzler MA; Vitko S; Duan T; Block A; Harler MB; Durrbach A
Am J Transplant; 2012 Mar; 12(3):630-9. PubMed ID: 22300431
[TBL] [Abstract][Full Text] [Related]
9. Belatacept: a new biologic and its role in kidney transplantation.
Su VC; Harrison J; Rogers C; Ensom MH
Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
[TBL] [Abstract][Full Text] [Related]
10. Belatacept utilization recommendations: an expert position.
Grinyó JM; Budde K; Citterio F; Charpentier B
Expert Opin Drug Saf; 2013 Jan; 12(1):111-22. PubMed ID: 23206310
[TBL] [Abstract][Full Text] [Related]
11. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).
Durrbach A; Pestana JM; Pearson T; Vincenti F; Garcia VD; Campistol J; Rial Mdel C; Florman S; Block A; Di Russo G; Xing J; Garg P; Grinyó J
Am J Transplant; 2010 Mar; 10(3):547-57. PubMed ID: 20415898
[TBL] [Abstract][Full Text] [Related]
12. An integrated safety profile analysis of belatacept in kidney transplant recipients.
Grinyó J; Charpentier B; Pestana JM; Vanrenterghem Y; Vincenti F; Reyes-Acevedo R; Apanovitch AM; Gujrathi S; Agarwal M; Thomas D; Larsen CP
Transplantation; 2010 Dec; 90(12):1521-7. PubMed ID: 21088650
[TBL] [Abstract][Full Text] [Related]
13. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.
Martin ST; Tichy EM; Gabardi S
Pharmacotherapy; 2011 Apr; 31(4):394-407. PubMed ID: 21449628
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
15. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Vincenti F; Charpentier B; Vanrenterghem Y; Rostaing L; Bresnahan B; Darji P; Massari P; Mondragon-Ramirez GA; Agarwal M; Di Russo G; Lin CS; Garg P; Larsen CP
Am J Transplant; 2010 Mar; 10(3):535-46. PubMed ID: 20415897
[TBL] [Abstract][Full Text] [Related]
16. Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens.
Chiodo Ortiz A; Petrossian G; Addonizio K; Hsiao A; Koizumi N; Yu Y; Plews R; Conti D; Ortiz J
Transpl Immunol; 2023 Feb; 76():101774. PubMed ID: 36528248
[TBL] [Abstract][Full Text] [Related]
17. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
[TBL] [Abstract][Full Text] [Related]
18. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
Charpentier B
Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
[TBL] [Abstract][Full Text] [Related]
19. Belatacept: in adult kidney transplant recipients.
Garnock-Jones KP
BioDrugs; 2012 Dec; 26(6):413-24. PubMed ID: 22928660
[TBL] [Abstract][Full Text] [Related]
20. Belatacept and Long-Term Outcomes in Kidney Transplantation.
Vincenti F; Rostaing L; Grinyo J; Rice K; Steinberg S; Gaite L; Moal MC; Mondragon-Ramirez GA; Kothari J; Polinsky MS; Meier-Kriesche HU; Munier S; Larsen CP
N Engl J Med; 2016 Jan; 374(4):333-43. PubMed ID: 26816011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]